Biomea Fusion Inc. (BMEA)
4.20
0.05 (1.20%)
At close: Jan 15, 2025, 10:00 AM
Company Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers.
The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion Inc.
| Country | United States |
| IPO Date | Apr 16, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 107 |
| CEO | Thomas Andrew Butler |
Contact Details
Address: 900 Middlefield Road Redwood City, California United States | |
| Website | https://biomeafusion.com |
Stock Details
| Ticker Symbol | BMEA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840439 |
| CUSIP Number | 09077A106 |
| ISIN Number | US09077A1060 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas Andrew Butler | Co-Founder, Chairman & Chief Executive Officer |
| Franco Valle CPA | Chief Financial Officer & Principal Accounting Officer |
| Naomi Cretcher | Chief People Officer |
| Ramses M. Erdtmann | Co-Founder, President, Chief Operating Officer & Director |
| Caroline Perez- Dupont | Senior Vice President of Contracts |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer |
| Dr. Stephan Morris M.D. | Chief Development Officer |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry |
| Heow Tan | Chief Technology & Quality Officer |
| Ravi Upasani | Executive Vice President of Intellectual Property |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 06, 2025 | S-8 | Filing |
| Dec 20, 2024 | 8-K | Current Report |
| Dec 02, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 10-Q | Quarterly Report |
| Oct 29, 2024 | 8-K | Current Report |
| Oct 01, 2024 | 4 | Filing |
| Sep 27, 2024 | 8-K | Current Report |
| Jul 31, 2024 | 10-Q | Quarterly Report |